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Research Article
Restoration of rostral cerebrospinal fluid flow
to solve treatment failure caused by
obstruction in long-term intrathecal baclofen
administration
Elmar M. Delhaas1,3, Biswadjiet S. Harhangi2, Pieter J. van Doormaal3,
Wouter Dinkelaar3, Ad C.G.M. van Es3, Danielle M.E. van Assema3,
Sander P.G. Frankema1, Aad van der Lugt3, Frank J.P.M. Huygen1
1Center for Pain Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands, 2Department of
Neurosurgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands, 3Department of Radiology and
Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands
Objects: We describe five traumatic spinal cord injury (SCI) patients with an intrathecal baclofen administration
(ITB) failure caused by a rostral CSF flow obstruction referred to our expert center between January 2014 and
January 2019. We discuss the diagnostic workup, rostral CSF flow obstruction as the cause of the ITB failure and
treatment.
Methods: When we could not determine the cause of the ITB failure through the patient’s history, physical
spasticity examination, pump readout, absence of fluid in the pump reservoir during aspiration, or plain
radiography, we performed pump catheter access port (computed tomography [CT]) myelography. When CT
myelography did not reveal the diagnosis, we used scintigraphy. In an obstruction, we aimed for CSF flow
restoration. In three cases, we conducted a laminectomy with microsurgical adhesiolysis. In two of these
patients, we could not achieve CSF flow restoration; thus, we placed an intradural catheter bypass. Recently,
in three patients, we applied a less invasive technique of percutaneous fenestration of the obstruction.
Results: In one case, we performed a successful catheter replacement. In another case using surgical
adhesiolysis, spasticity control was complete. In two cases, we could obtain improvement with an additional
intradural bypass, followed by a percutaneous fenestration of the obstruction, resulting in further improved
CSF flow restoration. In one case, percutaneous fenestration was the first line of treatment. In all cases with
percutaneous fenestration, we experienced spasticity control.
Conclusion: Preliminary results showed that the restoration of rostral CSF flow might result in an effective ITB
treatment in patients with an intrathecal obstruction.
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Introduction
Following a spinal cord injury (SCI), 62% to 88% of the
patients develop spasticity.1–4 Nonetheless, the resulting
muscle tone might have advantages, such as advantages
during transfers or as a clinical indicator of noxious
stimuli.5 In generalized spasticity, the GABA-B receptor
agonist baclofen is the most frequently used drug. Since
1984, intrathecal baclofen (ITB) has become an often
used therapy in intractable cases.6 A rostral cerebrosp-
inal fluid (CSF) flow obstruction is a rare cause of
long-term ITB failure. In this paper, we describe five
adult SCI patients with an ITB failure caused by a
rostral CSF flow obstruction. After CSF flow
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restoration either by microsurgical adhesiolysis, intra-
dural bypass,7,8 or percutaneous fenestration, we evalu-
ated the ITB treatment effect. CSF flow restoration was
attempted based on the following observations: a suc-
cessful clinical treatment with an intradural shunt in a
patient with a CSF flow obstruction (not published);
cerebral cistern visualization with 111Indium-diethy-
lene-triamine-penta-acetic acid scintigraphy (111In-
DTPA) in normal cases; the lack of treatment effect
when the catheter tip was placed above an obstruction;
and cerebral symptomatology, which occurred upon
an ITB overdose. Based on these observations, we
hypothesized that besides the regional effect of ITB,
rostral CSF flow is also needed for effective ITB treat-
ment, and that the restoration of rostral CSF flow in
obstructions could be a useful therapy in the case of
ITB failure.
Methods
The five patients were referred to our expert center for
ITB troubleshooting between January 2014 and
January 2019. In four of the five patients, catheter revi-
sion(s) had not resolved the ITB failure. All patients
used a SynchroMed II delivery system (Medtronic
Inc., Minneapolis, MN, USA). Five were treated with
baclofen only, and one with a combination of baclofen
and hydromorphone. During the diagnostic workup,
the rostral CSF flow obstruction was demonstrated
and treated via the restoration of the rostral CSF flow.
For this retrospective study, we received approval from
the medical ethics committee of the Erasmus Medical
Center (MEC-2017-326), and the requirement to
obtain informed consent was waived.
Diagnostic workup
When we could not determine the cause of ITB failure
through the patient’s history, physical examination of
the spasticity, pump readout, absence of fluid during
aspiration of the pump reservoir, plain radiography,
or low-dose CT, we performed pump catheter access
port (CAP) computed tomography (CT) myelogra-
phy.9 Via the CAP, we injected 10 ml of contrast
material (iohexol, Omnipaque™ 320, GE Healthcare
B.V., Eindhoven, The Netherlands), followed by
fluoroscopy and CT. Occasionally, we injected con-
trast material via a lumbar puncture when we could
not perform CAP myelography (Cases 3, 5). To
demonstrate the presence or absence of the rostral
spread of the injected contrast material, we used the
Trendelenburg position immediately after the contrast
material injection. The images were evaluated for an
inhomogeneous or reduced contrast material
distribution. To be informed about the length of the
intrathecal obstruction, we added cervical CT myelo-
graphy to the diagnostic algorithm9 (Cases 3, 4).
When in doubt of an obstruction, we additionally per-
formed 111In-DTPA (Cases 1, 2, 3). We mixed the
medication in the pump reservoir with 20 MBq of
111In-DTPA and standardized the pump flow rate for
each patient in such a manner that after 24 h the cath-
eter tip would be reached in the case of normal flow.
To maintain the same dose, we adapted the drug con-
centration in advance. A previous radioisotope study
showed that the tracer reaches the cerebral basal cis-
terns from the lowest caudal level in 2–2.5 h.10
Therefore, basal cisterns should be clearly visible at
111In-DTPA within 48 h. We assumed stagnation in
drug delivery due to a rostral CSF flow obstruction
when the tracer appearance in the basal cisterns was
later than 48 h, limited, or not present (Fig 1).
Summary of cases
We summarized the patient’s history, the used diagnostic
procedures exhibiting a partial or complete CSF
obstruction, and the treatment in Table 1.
Case 1
A 44-year-old man who experienced a traumatic SCI
American Spinal Injury Association (ASIA)-A at the
C5 level eight years ago developed disabling intract-
able spasticity of the lower and upper extremities.
After a successful ITB bolus injection test two years
later, the patient was successfully treated with ITB
for four years. However, the spasticity reoccurred
gradually despite a daily dose of 502 mcg. Several
higher doses did not result in an improvement, and
the patient was referred to our center. At the time of
referral, the patient had severe spasticity of the lower
and upper extremities (a Modified Ashworth Scale
[MAS] score of 3). CAP (CT) myelography was suspi-
cious of an obstruction at the T10 level (Fig. 2A and
B), which was confirmed by 111In-DTPA (Fig. 2C).
Because no catheter revisions were performed pre-
viously, we first replaced the intrathecal catheter,
which resulted in a clinically significant decrease of
the spastic symptoms (MAS 1) for, currently, 15
months.
Case 2
A 64-year-old man experienced a traumatic SCI
ASIA-A at the T9–10 level 24 years ago. Over the
years, the patient developed disabling therapy-resistant
generalized spasticity of the lower extremities, which
could be managed by oral spasmolytic medication.
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Nevertheless, after 20 years, his spasticity could no
longer be controlled by this medication. After a positive
ITB bolus injection test, the patient was successfully
treated with ITB for three years. Gradually, his spasti-
city worsened, which could be reduced to MAS 3 by
increasing to an extremely high daily dose of 1374
mcg. CAP CT myelography (Fig. 3A) and 111In-
DTPA, including Single Photon Emission Computed
Tomography (SPECT-CT) (Fig. 3B) and planar
images (Fig. 3C), were suspicious of an obstructed
spread of contrast material and tracer material, respect-
ively. We performed a laminectomy at T9–10 with a
midline dura opening. With a microscope, we observed
severe adhesions and crystalloid drug accumulation in
several loculations. We conducted adhesiolysis of the
fibrotic leptomeninges and removed the crystalloids,
which resulted in CSF flow restoration. After finishing
the surgery, the ITB dose was reduced arbitrarily by
50%. The next day, the patient was slightly sedated,
with completely flaccid legs. We cut the dose further
to 550 mcg, which was sufficient to control the patient’s
spasticity (MAS 0) for two years.
Case 3
A 47-year-old woman experienced a traumatic SCI
ASIA-B at the T10 level 18 years ago. The patient’s
rehabilitation was hindered by severe lumbar and low
thoracic pain and disabling generalized spasticity of
the lower extremities, leading to a bedridden situation
for about 18 months. After a positive ITB bolus injec-
tion test, the patient was successfully treated with ITB
for 12 years. Gradually, the patient experienced exacer-
bation of her spasticity and pain. Despite dose adap-
tations of both baclofen and morphine, and later
hydromorphone, her complaints were persistent. A cath-
eter revision did not relieve the pain and spasticity. For
troubleshooting, the patient was referred to our center.
At the time of referral, the patient had severe spasticity
of the lower extremities (MAS 3) with a daily ITB dose
of 683 mcg, and high pain scores (a Visual Analogue
Scale [VAS] score of 8) in the lumbar region with a
daily hydromorphone dose of 4.5 mg. We evaluated
her pain and performed local anesthetic lumbar
blocks, which did not reveal improvement. CAP (CT)
myelography indicated an inhomogeneous stagnation
Figure 1 Algorithm imaging of CSF flow obstruction.
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of contrast material just below the SCI level. 111In-
DTPA after 48 h showed an abnormal widening of the
tracer spread at the lumbar/low-thoracic transition, a
narrowed thoracic region, and no tracer activity in the
cisterns, suggesting an obstruction (Fig. 4B). We per-
formed a laminectomy at the T10–11 level. Under
microscopic vision, we performed an extensive local
adhesiolysis of the fibrotic leptomeninges, but we
could not restore the CSF flow. We decided not to
enlarge the laminectomy, but to place an intradural
catheter bypass7,8 from T9 to L2. After surgery, the
spasticity was under control (MAS 0) with a daily ITB
dose of 460 mcg, but the pain remained unchanged
despite a daily dose of 3.2 mg of hydromorphone. In
the three years following the intervention, severe spasti-
city with a daily ITB dose of 505 mcg reappeared (MAS
3). The patient underwent several pain treatments else-
where, but despite these treatments and a daily intrathe-
cal hydromorphone dose of 3.5 mg, the patient had a
high VAS score of 8 at the referral. 111In-DTPA includ-
ing SPECT found identical planar images as before the
surgical intervention, consistent with a nonfunctional
intrathecal bypass (Fig. 5A). Based on our experience
at the previous laminectomy where we were not aware
of the length of the intradural obstruction, we wanted
to be informed about the magnitude of the obstruction
in advance. Therefore, we performed lumbar dual-
energy CT (DECT) myelography with 3D reconstruc-
tions (Fig. 5B and C), and, in a second session, cervical
CT myelography (Fig. 5D and E). With the Seldinger
technique,11 we performed a percutaneous fenestration
of the obstruction with balloon dilatation. With the
patient in the prone position with 5 ml of lidocaine 1%
local infiltration, a midline lumbar puncture was per-
formed with an 18G Tuohy needle (B Braun Medical
B.V., Oss, The Netherlands). We inserted an Angled
Guidewire 0.035 (Terumo Benelux N.V., Leuven,
Belgium) into the intrathecal space, and advanced a
5F Brite Tip introduction sheath over the guidewire
(Cordis Cardinal Health B.V., Amsterdam, The
Netherlands). Via the sheath, we perforated the obstruc-
tion with the guidewire. In the next step, we advanced a
Table 1 Summary of patient history, diagnostic procedures, obstruction, and treatment.
Case 1 Case 2 Case 3 Case 4 Case 5
Sex male male female male male
Age 44 64 47 60 38
Level of SCI C5 T12 T10 T2 C6
Treatment somewhere else
Dose adjustments yes yes yes yes yes
Improvement none none none none none
Catheter revision N = 1 N = 3 N = 18
Improvement no no no
Intradural bypass C6–T6
Improvement no
111Indium scintigraphy
At referral
Spasticity severe severe severe severe severe
Pain severe
Years of successful ITB 4 3 12 19 <1
Baclofen dose (mcg/24 h) 502 1374 498 483 2216
Opioid dose (mg/24 h) Hydromorphone 2.2
Our diagnostics
Plain radiography normal normal normal normal normal
Catheter tip T7–8 T9–10 T11 T7 T9
Aspiration fluid CAP yes yes yes yes no
CAP myelography obstruction partial T7 partial T11 complete T10–11 complete T5–7
CAP CT myelography obstruction partial T7 partial T11 complete T10–11 complete T5–7
111Indium scintigraphy obstruction partial T7 partial T11 complete T9–10 complete T9
LP CT myelography obstruction complete T8–9 extradural catheter
CP CT myelography obstruction complete T10
Our treatment
None
Catheter revision yes yes
Improvement good some
Microsurgical adhesiolysis yes
Improvement excellent
Microsurgical adhesiolysis + Intradural bypass yes T8–L2 yes T6–10
Improvement some some
Percutaneous fenestration yes yes yes
Improvement good excellent good
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Figure 2 Catheter access port (CAP) myelography (A) showed stagnation of contrast material (black arrow). The catheter tip is
located above the contrast material (gray arrow). CAP CT myelography (B) with 4 consecutive sagittal reconstructions revealed a
caudal flow of the contrast material (white arrow). Planar 111Indium-DTPA scintigraphy 7 days (C) showed a limited rostral tracer
spread, increased lumbar/thoracic gradient (gray arrow), increased caudal spread (black arrow), and insufficient cerebral cistern
(white arrow).
Figure 3 CAP CT myelography (A) with 5 consecutive sagittal reconstructions revealed narrowed contrast material column (red
arrow), suspicious for contrast material stagnation. 111In-DTPA SPECT CT at 48 h (B) showed obstruction at the level of the spinal
cord lesion (red arrow). 111In-DTPA planar (C) revealed a lumbar/thoracic gradient (red arrow), limited cerebral cistern tracer spread
(orange arrow). In vivo microscopic view with opened dura showed intrathecal catheter tip (yellow arrow), forceps (blue arrow), and
baclofen medication crystallization (green arrow).
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5 × 120 mm 0.038 Admiral Xtreme balloon (Medtronic
Trading NL B.V., Eindhoven, The Netherlands) and
gradually inflated the balloon until reaching the pain
threshold. We deflated and repeated inflation several
times to achieve, if possible, optimal balloon expansion
at a nominal pressure of 8 bar. We controlled the dilata-
tion results with cervical myelography through the injec-
tion of 10 ml of iohexol 300 via the inserted sheet. After
each contrast material administration, we aspirated
10 ml of fluid to maintain intrathecal normovolemia.
We repeated the balloon inflation and deflation pro-
cedure on two lower levels. Immediately after successful
dilatation, the patient experienced severe nausea with
vomiting, which we explained by the sudden rostral
spread of the baclofen/hydromorphone medication.
As therapy for this intoxication, we aspirated 30 ml of
CSF and injected 1 mg of granisetron intravenously.
Within a couple of minutes, the patient’s spasticity
(MAS 0) and pain (VAS 0) disappeared entirely and
have remained absent for, currently, a period of six
months with a daily ITB dose of 505 mcg and an
intrathecal hydromorphone dose of 3.5 mg.
Case 4
A 64-year-old man experienced a traumatic SCI ASIA-
A at the T2 level 25 years ago. The patient developed
disabling therapy-resistant spasticity of the lower limbs
and the abdominal and thoracic region, which was com-
plicated by autonomic dysreflexia (AD) several times a
day, and which could insufficiently be controlled by
oral medication. Two years later, after a positive ITB
bolus injection test, the patient’s spasticity, as well as
his AD, was successfully treated with ITB for 15 years.
At the time of a pump replacement because of the end
of the battery life, the patient’s treating physician also
decided to replace the intrathecal catheter. From that
time onward, the severe spasticity with frequent daily
periods of AD could no longer be managed by ITB.
To overcome the ITB failure, the patient underwent
three catheter revisions without any result. At the time
of referral, the MAS score was 2. Nevertheless, the
patient had severe spontaneous and intentional spasms
Figure 4 Planar 111In-DTPA at 48 h (A, B). A patient without
CSF flow obstruction with normal lumbar, thoracic, and
cerebral cistern tracer spread (A). Case 4 with widened tracer
activity caudal and at lumbar/low-thoracic transition (B, black
arrow), thoracic gradient (B, gray arrow), and no cisternal tracer
spread (B, white arrow).
Figure 5 111In-SPECT CTwith stagnation of tracer (white arrow), non-functional intradural shunt (A, E, green arrow), and no tracer
activity above the tip of the shunt (A). Lumbar CT (3D) myelography with stagnation of contrast material at Th11 (B, C, white arrow),
and with cervical CT (3D) at Th10 (D, E, yellow arrow). Intrathecal catheter (red arrow).
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of the lower extremities and the abdominal and thoracic
region, and AD every hour. CAP CT myelography
(Fig. 6A) and cervical CT myelography (Fig. 6B)
revealed contrast material stagnation at the SCI level.
With the same percutaneous fenestration procedure
(Fig. 6D–J) as in Case 3, we could restore the rostral
CSF flow (Fig. 6C). Immediately after the successful
dilatation, the patient experienced nausea and a head-
ache, probably as a result of the sudden rostral spread
of the baclofen medication. We drained 30 ml of CSF
and injected 1 mg of granisetron intravenously. Within
a couple of minutes, his spasticity disappeared entirely.
After that, the ITB dose was titrated to 157 mcg,
which was sufficient to control his spasticity and AD,
and the additional 140 mg of daily oral baclofen medi-
cation could be stopped permanently. At this moment,
the result has lasted for six months.
Case 5
A 38-year-old man experienced a traumatic SCI ASIA-
B at the C6 level 19 years ago. The patient developed
disabling therapy-resistant spasticity of the lower extre-
mities, abdominal region, trunk, and right hand,
which could insufficiently be managed by oral spasmo-
lytic medication. After a positive ITB bolus injection
test two years later, the patient was successfully treated
with ITB for less than one year. In particular, spasticity
of the abdomen, trunk, and right hand was problematic.
Over 14 years, the patient underwent 18 surgical inter-
ventions to improve the ITB treatment, but all these pro-
cedures did not lessen his complaints. The patient was
referred to our center for troubleshooting. At the time
of referral, the patient had severe generalized spasticity
of the lower extremities and right hand, and severe spon-
taneous and intentional spasms of the abdominal region
and trunk several times a day, despite an extreme ITB
daily dose of 2216 mcg. During CAP myelography, we
could not aspirate CSF and, therefore, contrast material
was not injected, and we terminated the procedure.
111In-DTPA SPECT at 72 h and seven days via the
pump demonstrated tracer accumulation at the
lumbar–low thoracic transition, a stagnation of the
tracer at T2, and no activity in the cerebral cisterns.
CT myelography via L3–4 showed an extradural cath-
eter position. We inserted a new intrathecal catheter
with the tip on T10. Postoperatively, with a daily ITB
dose of 360 mcg, the spasticity of his lower extremities
was under control, but the spasticity of his abdomen,
trunk, and right hand was not. Dose increments up to
1109 mcg did not improve the situation. With magnetic
resonance imaging (MRI), a granuloma was excluded.
Because of the persistent complaints two months later,
an 111In-DTPA was performed, and a tracer stop at
the catheter tip and minimal activity in the cerebral cis-
terns were found, consistent with an obstruction at the
catheter tip level. We performed a laminectomy at the
T10–11 level and found an intact intrathecal catheter.
With a microscope, we observed severe adhesions and
crystalloid drug accumulation in several loculations.
We conducted extensive local adhesiolysis, but we
could not restore the CSF flow. We decided not to
extend the laminectomy, but to place an intradural cath-
eter bypass7,8 from T10 to C6. Following the surgery,
the spasticity improved, but the trunk and upper extre-
mity remained problematic, despite the high daily ITB
dose of 1109 mcg. Two years later, we performed a per-
cutaneous fenestration of the obstruction. During a
lumbar puncture at the L2–3 level, minimal spon-
taneous CSF flow was observed. We experienced a
Figure 6 CAP myelography (A) and cervical CT myelography
(B) with inhomogeneous stagnation (white arrow). Cervical CT
myelography after percutaneous balloon fenestration (C) with
restoration of contrast material spread (white arrow).
Fluoroscopy during the procedure with inserted balloon (D,
gray arrow). Cervical contrast material injection to evaluate the
effect of balloon dilatation (black arrow): starting situation (E),
some widening on the same level (F, G), and the result of the
fenestration (I–J).
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hindrance advancing the guidewire at several thoracic
levels. By moving the guidewire back and forth, we
could overcome the problem. We advanced the sheath
over the guidewire and inserted the balloon. With
repeated balloon inflation and deflation on the low thor-
acic level, we could manage several obstructions. When
reaching level C7, we observed a massive obstruction.
At this moment, the patient was complaining of a
severe headache, mild autonomic dysreflexia (only tran-
spiration and piloerection), and exacerbation of the
abdominal spasticity. We terminated the procedure,
reduced the daily dose to 500 mcg, and treated the head-
ache with paracetamol. After removing the balloon out
of the sheath, we observed spontaneous CSF flow,
although less than normal. The CT scan immediately
after the procedure revealed improvement of the CSF
flow; but at the lumbar and cervical levels – and less
at the thoracic level – some obstructions were still
present. The next day, his spasticity considerably
improved to MAS 1, and the paroxysmal spasms
almost completely disappeared. Until now, the result
has lasted for four months.
Discussion
Treatment results
This small case series showed that rostral CSF flow res-
toration could solve ITB failure in SCI patients with an
intrathecal flow obstruction. All patients had a previous
successful ITB bolus injection test and were, therefore,
suitable candidates for long-term ITB. As a conse-
quence, the short benefit duration in one patient was
unexpected, while the other four patients had successful
ITB for years.
Adhesions
In line with the literature,8 we identified peroperatively
severe adhesions in three patients and, in two, even crys-
talloid drug accumulation in several loculations. We
observed a rostral CSF flow obstruction as the cause
of ITB failure only in traumatic SCI patients, and not
in other ITB patients. There probably may be a relation-
ship with the original trauma or the previous posttrau-
matic neurosurgical intervention. It could be assumed
that the obstruction existed already at the start of the
ITB treatment. However, the experience of excellent
treatment for years, which is also reported in the litera-
ture,8 more likely suggests a CSF flow hindrance during
the course of the ITB treatment. We had no information
about the preexisting arachnoiditis in the referred
patients. In our opinion, it is not common practice to
evaluate arachnoiditis before starting ITB. Even when
arachnoiditis, known or unknown, is present, patients
will be treated with ITB after a positive diagnostic ITB
bolus test. The observed loculations may develop after
focal arachnoiditis resulting in fibroconnective adhe-
sions,12 whereby the leptomeninges will give rise to locu-
lation formation.13 This may lead to accumulation of
the infused medication, which is what we found
(Fig. 3D). The accumulation of drugs will give rise to
a high local concentration, which in turn can lead to a
vicious cycle of chronic arachnoiditis. It is assumed
that the longer the exposure, the higher the probability
that a toxic response to the drug will occur.14 In
chronic intrathecal infusion of morphine and hydromor-
phone, arachnoiditis may result in the formation of
space-occupying masses (granuloma) in the intrathecal
space.15,16 This phenomenon was recently supported
by a relationship between granuloma formation and
local mast cell degeneration in intrathecally adminis-
tered drugs.17 Such an association was found for mor-
phine and hydromorphone, but not for baclofen.17
The difference between the mentioned opioids and
baclofen is in accordance with clinical experience, in
which granuloma formation is a well-known compli-
cation of intrathecally administered opioids,15,16 but
rare when using intrathecal baclofen.18–20 The extremely
low incidence of the reported clinical granuloma for-
mation in chronic ITB and the absence of factors of
granuloma development in animals and mast cell cul-
tures17 make the etiology of obstruction in SCI patients
treated with ITB unclear.
Imaging
To be certain of a CSF flow obstruction, the
Trendelenburg position is crucial in CAP (CT) or con-
ventional lumbar CT myelography. When in doubt if
an obstruction is present, the dynamic 111In-DTPA
often revealed the cause of the ITB failure. In a complete
obstruction, the observed tracer widening and caudal
tracer collection on the images are probably the result
of a backflow.
Interventions
After the success of the first case, we also intended to
perform an operative adhesiolysis in two other patients.
However, despite extensive local adhesiolysis, we could
not restore the CSF flow. We decided not to extend
the laminectomy, but to apply an intradural catheter
shunt. With the shunt, we could obtain improvement
in both cases, although not in the trunk and the right-
hand spasticity in one patient. Based on our recent
experience with promising results, we now prefer the
less invasive percutaneous fenestration as the first step
in rostral CSF flow restoration. To prevent a multi-
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segmental laminectomy, the percutaneous technique
also has the advantage in a more extended length
obstruction. The method has a potential risk of
damage in ASIA-B patients in particular (Case 3). We
regarded this as a calculated risk in a severely suffering
patient after an insufficient result from visual microsur-
gical adhesiolysis. This risk was extensively discussed in
advance with the patient. During the procedure, we
inflated the small diameter dilatation balloon in
several steps in such a way that compression on the
spinal cord was minimal. All the procedures were per-
formed with a continuous awake monitoring of the
patient to recognize potential damage. Before the pro-
cedure, we extensively discussed the pros and cons of
the treatment. Another issue could be that in the
future, epidural stimulation could be of benefit.
Traumatic adhesiolysis may interfere with epidural
stimulation, as this is reliant on viable axons remaining
at the site of the injury. For the moment, we will be con-
fronted with ITB failures with, besides adhesiolysis, no
other treatment options. A larger group of patients
and basic research are needed for the full elucidation
of the effect of the restoration. When the balloon
inflation will not meet our expectations, we will consider
surgical adhesiolysis with or without a bypass.
Needed rostral CSF flow
We hypothesized that rostral CSF flow is also needed for
ITB administration to be effective. This is in contradic-
tion to the current view of a solely local segmental ITB
effect.21–23 With rostral CSF flow restoration either by
surgical adhesiolysis, intradural bypass, or percutaneous
balloon fenestration, we could obtain improvement in
the five treated patients. These preliminary results sup-
ported our hypothesis and implied that an intervention
to restore the flow could solve an ITB failure caused
by a CSF flow obstruction. A recently published case
report8 of the successful use of a subarachnoid-subar-
achnoid shunt seems to support our results.
Autonomic dysreflexia control
From our own clinical experience with various ITB fail-
ures, we know that an ITB failure will not only lead to
the reoccurrence of severe intractable spasticity, but in
high SCI levels, also to the lack of autonomic dysreflexia
control (Case 4),24,25 a syndrome that can even be life-
threatening.26–29 These features justify extended diag-
nostic procedures and attempts to find a solution for
ITB failure, and not merely to accept ITB tolerance as
an exacerbation of the underlying disorder.
Duration of the clinical effect
How long the achieved result will last and whether we
can repeat the procedure in the case of recurrent
failure are uncertain. A larger group of patients and
basic research are needed for the full elucidation of the
effect of the restoration of CSF flow.
Conclusion
Preliminary results showed that the restoration of the
rostral CSF flow might result in an effective ITB treat-
ment in patients with an intrathecal obstruction.
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